We have reported here a retrospective observational survey of 12 Romanian children and adolescents with severe allergic asthma, which demonstrated that they benefited from additional anti-IgE monoclonal antibodies (Omalizumab) therapy for high-level maintenance treatment. This evidence concerns the gene IGHE and allergic asthma.